Pruritus · chronic pruritus of unknown origin
Serlopitant 1 mg showed no clear difference in patient‐reported pruritus intensity compared with placebo (low certainty).
1 finding from 1 review
Adverse events · chronic pruritus of unknown origin
It is very uncertain whether serlopitant 1 mg changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Health‐related quality of life · chronic pruritus of unknown origin
1 finding from 1 review
Withdrawals due to adverse events · people with atopic dermatitis
1 finding from 1 review
Minor adverse events not leading to withdrawal of treatment · people with atopic dermatitis
1 finding from 1 review
Microbiology Emergence of resistant organisms · people with atopic dermatitis
1 finding from 1 review
Global change in composite ratings scale EASI ranges from 0 to 72 with higher values indicating greater severity. · people with atopic dermatitis
1 finding from 1 review
No of participants in whom S. aureus was isolated · people with atopic dermatitis
Oral antibiotic showed no clear difference in no of participants in whom S. aureus was isolated compared with placebo (low certainty).
1 finding from 1 review
Global outcome (good or excellent improvement in symptoms or signs, or both) · people with atopic dermatitis
Bleach bath showed no clear difference in global outcome (good or excellent improvement in symptoms or signs,… compared with placebo or bath emollient (low certainty).
1 finding from 1 review
Change from baseline in quality of life CDLQI ranges from 0 to 30 with higher values indicating more impaired quality of life. · people with atopic dermatitis
1 finding from 1 review
Withdrawals due to adverse events · people with atopic dermatitis
1 finding from 1 review
Minor adverse events not leading to withdrawal of treatment · people with atopic dermatitis
Bleach bath showed no clear difference in minor adverse events not requiring withdrawal from treatment compared with placebo or bath emollient (low certainty).
1 finding from 1 review
Microbiology Emergence of resistant organisms · people with atopic dermatitis
1 finding from 1 review
Global change in composite ratings scale EASI ranges from 0 to 72 with higher values indicating greater severity. · people with atopic dermatitis
1 finding from 1 review
No of participants in whom S. aureus was isolated · people with atopic dermatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global outcome (good or excellent improvement in symptoms or signs, or both) · people with atopic dermatitis
Oral antibiotic showed no clear difference in global outcome (good or excellent improvement in symptoms or signs,… compared with placebo (low certainty).
1 finding from 1 review
Change from baseline in quality of life IDQoL ranges from 0 to 30 with higher values indicating more impaired quality of life. · people with atopic dermatitis
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 30 mg leads to higher primary: investigator‐rated good/excellent control of symptoms compared with placebo (high certainty).
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 30 mg leads to higher primary: participant‐rated good/excellent control of symptoms… compared with placebo (high certainty).
1 finding from 1 review
Adverse effects: headache · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 30 mg leads to higher primary: adverse events ‐ headache Folluw‐up: 48 weeks to 72 weeks compared with placebo (high certainty).
1 finding from 1 review